Oliver Pohl
Geneve, GE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD.
Journal: Biomedicines
Published: March 22, 2024
A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis.
Journal: British journal of clinical pharmacology
Published: April 13, 2021
Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers.
Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers.
Journal: Scientific reports
Published: September 24, 2020
The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers.
Journal: Reproductive biomedicine online
Published: August 19, 2020
Effect of the oxytocin receptor antagonist nolasiban on pregnancy rates in women undergoing embryo transfer following IVF: analysis of three randomised clinical trials.
Journal: Human reproduction (Oxford, England)
Published: June 16, 2020
Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern.
Journal: Reproductive sciences (Thousand Oaks, Calif.)
Published: March 07, 2019
Oxytocin Receptor Antagonists, Atosiban and Nolasiban, Inhibit Prostaglandin F2α-induced Contractions and Inflammatory Responses in Human Myometrium.
Journal: Scientific reports
Published: November 22, 2018
Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone.
Journal: British journal of clinical pharmacology
Published: August 21, 2018
Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs.
Journal: Therapeutic innovation & regulatory science
Published: June 15, 2018
OBE022, an Oral and Selective Prostaglandin F2α Receptor Antagonist as an Effective and Safe Modality for the Treatment of Preterm Labor.
Journal: The Journal of pharmacology and experimental therapeutics
Published: February 26, 2018
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.
Journal: British journal of clinical pharmacology
Published: February 19, 2018
Confirmation of the Cardiac Safety of PGF2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments.
Journal: Clinical pharmacology in drug development
Published: September 22, 2017
Last Updated: 09/26/2026